Cyclooxygenase-2 (COX-2), a rate limiting step in arachidonic acid cascade, plays a key role in the biosynthesis of prostaglandin E 2 (PGE 2 ) upon inflammatory stimuli, growth factors, hormones and other cellular stresses. Overproduction of PGE 2 stimulates proliferation of various cancer cells, confers resistance to apoptosis and favors metastasis and angiogenesis.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and has an increasing incidence in western countries (Llovet and Bruix, 2008) . Although the risk factors for HCC are well characterized, the molecular pathogenesis of this tumor type is not well understood, and thus the identification of new possible targets for the development of nonconventional treatments is urgent and must be improved (Hoshida et al. , 2009 , Lee et al. , 2004 ).
Cyclooxygenase-1 (COX-1) and -2 catalyze the first step in prostanoid biosynthesis. COX-1 is constitutively expressed in many tissues, whereas COX-2 is induced by a variety of stimuli such as growth factors, pro-inflammatory stimuli, hormones and other cellular stresses (Simmons et al. , 2004) . Adult hepatocytes fail to induce COX-2 expression regardless of the pro-inflammatory factors used (Martin-Sanz et al. , 1998) . However, our group and others demonstrated that partial hepatectomy (PH) induced COX-2 in hepatocytes and contributed to the progression of cell cycle after PH (Casado et al. , 2001 , Rudnick et al. , 2001 ). In addition to liver regeneration after PH, expression of COX-2 has been observed in animal models of cirrhosis (Yamamoto et al. , 2003) , in human hepatoma cell lines (Kern et al. , 2006 , Mayoral et al. , 2005 , in human HCC (Cusimano et al. , 2009 ) and after HBV and HCV infection (Cheng et al. , 2008 , Nunez et al. , 2004 . The second key enzyme that couples with COX-2 for the synthesis of PGE 2 is PGE 2 synthase (PGES). Three types of PGES participating in the synthesis of PGE 2 have been described: one cytosolic (cPGES) and two membrane-associated PGES (mPGES-1 and -2). Coupling with COXs, these two types of PGES display different functions. cPGES is a cytosolic protein identical to the Hsp90-associated protein 23, which is a cofactor for the molecular chaperone function of Hsp90. It is constitutively expressed in many cell types and is predominantly coupled with COX-1. mPGES-1 is an inducible enzyme which belongs to the membrane-associated proteins involved in eicosanoid and glutathione 4 metabolism (MAPEG) superfamily, catalyzes the synthesis of PGE 2 commonly found in epithelial cells and is upregulated during inflammatory conditions (Diaz-Munoz et al. , 2012 , Subbaramaiah et al. , 2004 . Recently, more evidence has suggested that mPGES-1 participates in various pathophysiological states in which COX-2 is involved. Consistent with the role of mPGES-1 for PGE 2 synthesis, mPGES-1 knockdown has been shown to inhibit PGE 2 production and reduce tumor proliferation and/or invasiveness of several tumor cell types including Lewis lung carcinoma cells, human prostate cancer cell lines and colorectal cancer cells, through a novel EGR1/β-catenin signaling axis (Sasaki et al. , 2011) .
In tumors the steady-state level of PGE 2 is maintained by the biosynthetic pathway including both types of PGES, mPGES and cPGES and the catabolic pathways involving 15-PGDH. 15-PGDH is a crucial enzyme responsible for the biological inactivation of PGE 2 which induces cell proliferation, migration, angiogenesis and tumor metastasis (Na et al. , 2011) . 15-PGDH metabolizes PGE 2 by oxidizing the 15(S)-hydroxyl group into a keto group producing 15-keto PGE 2 . Genetic deletion of 15-PGDH leads to increased tissue levels of PGE 2 . Although previous studies on the distribution and activity of 15-PGDH have focused primarily in parturition and uterine biology, recent data suggest that 15-PGDH plays an important role in carcinogenesis. 15-PGDH is a tumor suppressor in gastrointestinal, colorectal, breast and lung cancers (Ding et al. , 2005 , Wolf et al. , 2006 , Yan et al. , 2004 .
However, a high expression of 15-PGDH as well as COX-2 was observed in a malignant ovarian tissue and the expression of 15-PGDH was induced by some cytokines, by the tumor promoter phorbol 12-myristate 13 acetate (PMA) and by sex hormone, suggesting a possible involvement of this enzyme in the carcinogenic process as well (Tong and Tai, 2004) .
Keeping in mind these data we evaluated the potential role of 15-PGDH in hepatoma cells.
Our results show that 15-PGDH is downregulated in those human hepatoma cells with a high COX-2 expression, in chemical and genetic murine models of HCC and in human liver HCC biopsies. Moreover, 15-PGDH expression is regulated by EGF and HGF mainly through PI3K, ERK and p38 MAPK and over expression of 15-PGDH induces apoptosis in hepatoma cells.
MATERIALS AND METHODS

Patients:
Eighteen individual tumoral and paired non-tumoral frozen HCC tumors were obtained from de Spanish Tumor Bank Network of the Centro Nacional de Investigaciones Oncológicas (CNIO). Institutional review board approval (Nº PI. CEI PI 20_2011) was obtained for these studies and all participants provided written informed consent. All tissues were evaluated by pathologists by means of hematoxylin/eosin staining. Tissues were snapfrozen in liquid nitrogen and total RNA was isolated as described in supplementary.
2.1.1. Immunohistochemical staining: 2-4 µm thick paraffin-embedded tissue microarrays (TMAs) and complete sections were cut onto Dako slices (DAKO, Glostrup, Denmark) by Immunohistochemistry Unit of CNIO, and subsequently dewaxed, rehydrated and subjected to antigen retrieval by heating in PTLink with 50 mM Tris/EDTA, pH 9.0. The slides were cooled and treated with peroxidase-blocking solution (DAKO) for 5 min. Sections were immunostained with a 15-PGDH antibody (NeoMarkers, Suffolk, UK), in a Autostainer Plus (DAKO). In parallel, each tissue section was also incubated with a goat anti-rabbit antiserum (negative control). Microphotographs were taken with an EnVision FLEX system. The images were processed with Image J software. Integrated density was calculated for each image after background subtraction. The background corresponds to the immunoreactivity in the positive control tissue (normal liver).
Animal models:
Mice (25-30g body weight) on a C57BL6JxDBA background were used in this study. The animals were housed on a 12 h light/12 h dark cycle in an air conditioned room at 25ºC with food and water available ad libitum. To induce HCC, diethylnitrosamine (DEN) (25 mg/Kg body weight, Sigma) was injected intraperitoneally 6 (i.p.) into 14 day old mice. Mice were sacrificed at 10 and 40 wk after DEN treatment, their body and liver weights were recorded and their livers removed and separated into individual lobes. Mice were characterized as described by Llorente Izquierdo et al. (Llorente Izquierdo et al. , 2011) . Liver tissues were snap frozen in liquid nitrogen and stored at -80ºC. Moreover, a genetic model of HCC was used. Alb-c-myc (c-myc) and MT-TGF-α (TGF-α) singletransgenic mice were kindly obtained from Dr. S.S. Thorgeirsson (National Cancer Institute, Bethesda, Maryland). Generation of c-myc/TGF-α double transgenic mice was achieved by crossing homozygous B6CBA c-myc and CD-1 TGF-α mouse as described previously (Santoni-Rugiu et al. , 1998) . Expression of TGF-α driven by metallothionein I promoter was maintained by giving mice 50 mM ZnCl 2 in drinking water starting at weaning. All the experiments were performed in accordance with the animal care guidelines of the European Union (2010/63/EU), and approved by the Bioethical Committee from Consejo Superior de Investigaciones Científicas (reference project SAF2010/16037). Male were sacrificed after 5 and 9 months of age and their body and liver weights were recorded before the liver tissues were used for analysis. Wt mice were sacrificed at 9 months-old. Externally visible tumors (> 0.5mm) were analyzed using the Metamorph software (Universal Imaging Corp, West Chester, PA, USA). Liver tissues were snap frozen in liquid nitrogen and stored at -80ºC or fixed in 10% buffered formalin. Plasma was obtained from cardiac puncture or from the aorta.
Cell culture:
The human liver cell lines WRL68, Chang liver (CHL) and the hepatoma cell lines HepG2 and Hep3B were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). HuH-6 and HuH-7 cell lines were kindly provided by Dr. Perret (Institut Cochin, CNRS UMR8104, University Paris-Descartes, Paris, France) (de La Coste et al. , 1998) and Dr. Kern (Department of General Pathology, University Hospital Heidelberg, Heidelberg, Germany) (Kern et al. , 2002) , respectively. Human cell lines authentication and intra-species cell line cross-contamination were analyzed using 
RESULTS
15-PGDH and COX-2 expression correlate inversely in hepatoma cell lines. COX-2,
mPGES-1 and 15-PGDH protein and mRNA levels were analyzed in four hepatoma (HCC) cell lines (HepG2, Hep3B, HuH-7, HuH-6), in a cell line derived from human liver embryo (WRL68) and in a cell line derived from normal liver (CHL), using human hepatocytes (HH)
as control ( Fig. 1A-D ). Each cell line expresses different levels of COX-2, mPGES-1 and 15-PGDH mRNA and protein. WRL68 exhibited the highest COX-2 and mPGES-1 expression levels followed for Hep3B and HuH-7 liver carcinomas, whereas CHL, HepG2 and HuH-6
showed low levels of COX-2 and mPGES-1 (Fig. 1A -B-C). Interestingly, the COX-2 positive-expression cell lines WRL68, Hep3B and HuH-7 displayed the lowest 15-PGDH mRNA and protein levels ( Fig. 1A-D) . PGE 2 levels correlate with those of the COX-2 and mPGES-1 expression, as well as the decrease of 15-PGDH levels ( Fig. 1E ). To determine whether exits a relationship between COX-2 and 15-PGDH expression in the HCC cell lines, the COX-2 protein/15-PGDH protein ratio was calculated showing an inverse linear correlation (R 2 =0.8524, P=0.0238) (Fig. 1F ). 
15-PGDH is downregulated by EGF in hepatic human cell line.
Previous reports indicated that EGF and HGF challenges upregulate COX-2 and downregulate 15-PGDH expression in several carcinomas (Donnini et al. , 2011 , Moore et al. , 2009 ). Our results demonstrate that EGF increased COX-2 and mPGES-1 levels in CHL cells ( Fig. 2A) . In addition to this, EGF decreased 15-PGDH protein levels in a concentration-dependent manner ( Fig. 2A) . Moreover, treatment of CHL cells with 50 ng/ml of EGF induced a marked increase of COX-2 and mPGES-1 protein and mRNA levels that reached a maximum at 48h and 6h, respectively ( Fig. 2B-C) . Furthermore, 50 ng/ml of EGF downregulated 15-PGDH protein and mRNA levels ( 
15-PGDH decrease induced by EGF involves EGFR, PI3K, MEK /ERK-MAPK and p38-MAPK signaling pathways in CHL cells.
CHL cells were incubated with different pharmacological inhibitors of key regulatory pathways and then challenged with EGF. Fig. 3A shows that COX-2 expression was downregulated by LY29402 and Erlotinib, suggesting that EGF-induced COX-2 expression was EGFR-dependent and involved PI3K signaling. Furthermore, 15-PGDH protein levels were upregulated by LY29402, SB202190, PD98059 and Erlotinib (Fig. 3A) suggesting that 15-PGDH expression decreased by EGF was EGFR-dependent and involved PI3K, p38
MAPK and MEK/ERK MAPK signaling. Next, we investigate whether exogenous PGE 2 participates in the 15-PGDH downregulation induced by EGF in CHL cells. As Fig. 3B shows, COX-2 protein levels were not modified by treatment with DFU and PGE 2 . In parallel 15-PGDH protein levels were not altered after COX-2 inhibition with DFU; however, PGE 2 treatment increased 15-PGDH protein levels, suggesting a positive feed-back mechanism, which is interrupted by EGF (Fig. 3B ). To substantiate further our results, HepG2 and CHL cells were silenced for 15-PGDH using specific siRNAs. COX-2 expression increased and the opposite was found when the cells were transfected with an expression vector for 15-PGDH.
Moreover, when WRL68 cells were silenced for COX-2 using specific siRNAs, 15-PGDH expression increased. These results suggest a complex interplay between COX-2 and 15-PGDH in some hepatoma cells ( Supplementary Fig. S2A-C) .
15-PGDH expression decreases HCC cell viability and induces apoptosis.
To further evaluate the effect of 15-PGDH in HCC cells outcome, we tested whether 15- Fig. 4D and S3D-F) and an increase (219%) in apoptosis (Fig. 4E ).
Apoptosis was confirmed by measurement of caspase-3 activity and the expression of some pro-and anti-apoptotic proteins. 15-PGDH overexpression induced an increase in caspase-3 activity ( Fig. 4F ) and in the expression of the pro-apoptotic proteins Bax and Bid (Fig. 4G) , whereas the expression of anti-apoptotic proteins Bcl-2 and Bcl-xL was decreased (Fig. 4H) .
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These results suggest that 15-PGDH may exert its anti-tumoral effects partially through induction of apoptosis.
15-PGDH decreases the growth of hepatoma cells in vivo.
To further analyze the effect of 15-PGDH on hepatoma cell growth in vivo, HepG2 cells were targeted to modulate 15-PGDH levels and cells were subcutaneously injected into athymic nu/nu mice. The mice were followed by the observation of xenograft growth for 3 weeks. We found that 15-PGDH led to a significant reduction in the volume and weight of the tumor comparing with the mice injected with control vector. Transfection with siPGDH increased the volume and the weight of tumors vs. scRNA ( Fig. 4I-J) . These results agree with the in vitro data and suggest that 15-PGDH inhibits the proliferation of hepatoma cells by inducing apoptosis.
15-PGDH expression in murine models of HCC.
To determine the role of 15-PGDH in HCC development, mice were injected with DEN (25 mg/kg) at the 14th postnatal day and sacrificed 10 and 40 wk after treatment. Plasma levels of liver injury markers after DEN treatment were analyzed in supplementary Table I . There was an important increase of AST and ALT after DEN treatment compared with the untreated mice. In addition, morphometric analysis revealed important differences in the number and size of detectable tumors at 40 wk compared with 10 wk after DEN treatment (Fig. 5A ). This would be coupled with the histopathological analysis of the liver biopsies indicating preneoplasic lesions (8%) in mice at 10 wk after DEN and HCC (100%) in mice at 40 wk after DEN and lung metastases (25%) ( Table I ). Histological analysis confirmed that all tumors at 40 wk after DEN treatment corresponded to liver carcinomas (Fig. 5B ). Tumors at 40 wk after DEN were positive for α-fetoprotein expression (not shown). Furthermore, 15-PGDH decreased at 10 wk after DEN treatment and was negligible in the non-tumor and tumor tissue at 40 wk after treatment compared with normal liver (Fig. 5C ). We also analyzed the profile of 15-PGDH in the double transgenic mice c-myc/TGF-α, a genetic model of HCC. Plasma levels of liver injury markers and the incidence of pathological signs are given in supplementary Table II . The morphometric analysis revealed significant differences in the number and size of detectable tumors in c-myc/TGF-α mice at 9 months old compared with 5 months-old mice (Fig. 5D) . Most of the c-myc/TGF-α double transgenic mice sacrificed at 5-months-old-age had preneoplasic foci (93.3%) (supplementary Table II) .
Furthermore, histological analysis of liver biopsies showed a tendency to develop adenomas (26.7%). After 9 months, >89% of Tg mice displayed HCC (supplementary Table II and Fig.   5E ). Interestingly, 15-PGDH protein levels were undetectable in the tumors generated by cmyc/TGF-α stably expression (Fig. 5F ) compared with normal liver. The double transgenic was verified by c-myc and TGF-α protein expression (Fig. 5F ).
Downregulation of 15-PGDH mRNA and protein expression in HCC human biopsies.
To extend our studies and assess the biological relevance of these observations in cell lines and murine models, we examined the 15-PGDH expression in 11 clinical samples of HCC and normal liver in a tissue microarray for immunohistochemistry analysis. A high 15-PGDH expression in normal liver tissue was detected (Fig. 6Aa) , whereas in HCC tissue biopsies 15-PGDH was significantly lesser expressed (Fig. 6Ab, c and 6B ). Immunoreactivity of 15-PGDH protein ranged from 61% to 0.09% vs. normal liver (100%, Fig. 6B ). The average of 15-PGDH immunoreactivity measurements was statistically significant compared with normal liver (Fig. 6C ). In agreement with those observations, mRNA 15-PGDH expression in 18 individual tumoral (T) and paired non-tumoral (NT) HCC human samples showed higher levels in NT tissue compared to T tissue (P=0.0322) (Fig. 6D ). These data support the hypothesis that 15-PGDH expression is downregulated in HCC. 
Several lines of evidence suggest that COX-2 signaling is implicated in hepatocarcinogenesis
and that COX-2 inhibitors prevent HCC cell growth in vitro and in animal models (Kern et al. , 2004) . Increased COX-2 expression has been found in human HCC; however, although COX-2 is elevated in the early stages of HCC, many questions remain unsolved regarding the sufficiency of COX-2 to induce/contribute to tumorigenesis (Cusimano, Fodera, 2009 ). Our previous work demonstrated that constitutive COX-2 expression in mice liver is not sufficient to enhance malignant transformation induced by DEN (Llorente Izquierdo, Mayoral, 2011) . Regarding mPGES-1, it participates in various pathophysiological states in which COX-2 is involved. Consistent with the role of mPGES-1 for PGE 2 synthesis, mPGES-1 knockdown has been shown to reduce PGE 2 levels and reduce tumor proliferation and/or invasiveness in several tumor cell types through a EGR1/β-catenin signaling axis (Donnini, Finetti, 2011 , Sasaki, Kamei, 2011 . The third enzyme involved in PGE 2 homeostasis, 15-PGDH, also plays an important role in carcinogenesis. 15-PGDH is downregulated and is a tumor suppressor in gastrointestinal, breast and lung cancers (Ding, Tong, 2005 , Lou et al. , 2012 , Wolf, O'Kelly, 2006 , Yan, Rerko, 2004 . 15-PGDH catalyzes the rate 14 limiting step of PG catabolism and thus represents a physiological antagonist of COX-2 (Backlund et al. , 2005) . Recent emerging evidence suggests that elevated PGE 2 in cancers may be the result of enhanced COX-2 mediated PGE 2 synthesis, but also to reduced 15-PGDH-dependent degradation. Although COX-2 expression in HCC has been extensively studied there are few data concerning mPGES-1 and 15-PGDH involvement in HCC (Cusimano, Fodera, 2009 , Kern, Schoneweiss, 2004 , Koga et al. , 1999 , Llorente Izquierdo, Mayoral, 2011 . Lim et al. reported that omega-3 polyunsaturated fatty acids inhibited PGE 2 signaling through decreased of COX-2 and expression of 15-PGDH in HCC cell lines (Lim et al. , 2009 ). In hepatoma cell lines our data show different levels of COX-2, mPGES-1 and 15-PGDH. Interestingly, there was a direct linear correlation between COX-2 and mPGES-1
and an inverse correlation between COX-2 and 15-PGDH. PGE 2 levels paralleled COX-2 and mPGES-1 expression.
The EGF and HGF signaling pathways upregulate COX-2 expression in different cancer cell types and downregulate 15-PGDH expression in several carcinomas (Donnini, Finetti, 2011 , Moore, Greenhough, 2009 , Tai, Chi, 2011 . Inhibition of Met expression increased 15-PGDH levels and both ERK and Akt signaling pathways were required for the COX-2 rise and 15-PGDH decrease (Moore, Greenhough, 2009) . Backlund et al. showed that a tyrosine kinase inhibitor, Erlotinib, increased the levels of 15-PGDH in colorectal cancer cell lines and this effect was mimicked by a MEK inhibitor (Backlund, Mann, 2005) There are different reports concerning the role of 15-PGDH in in vivo models of colon cancer.
In the APC Min mouse that spontaneously develop preinvasive adenomas that recapitulate many aspects of the human syndrome, familial adenomatous polyposis coli pathology, 15-PGDH was observed in the well differentiated villi from wild type mice, whereas it was absent in adenomas from APC Min/+ mice , Mann, Backlund, 2006 . Izquierdo, Mayoral, 2011 , Santoni-Rugiu, Jensen, 1998 . In agreement with this data we observed a decreased viability in HepG2 cells expressing of 15-PGDH both in in vitro and in in vivo assays when explanted in nude mice, these effects being reverted after reduction of 15-PGDH levels.
Moreover, 15-PGDH expression has been also analyzed in human colorectal cancer and in human lung cancer. The expression pattern of 15-PGDH was reduced in microdissected early hyperplasic lesions and in colorectal carcinomas suggesting that 15-PGDH plays a role in prevention of tumor progression (Ding, Tong, 2005 , Lou, Jing, 2012 , Mann, Backlund, 2006 .
Our data in human biopsies of HCC show a high 15-PGDH expression in normal liver tissue and a lesser content in ca. 90%, in tumor tissue biopsies from patients with HCC at the time that hepatoma cells overexpressing 15-PGDH show enhanced levels of pro-apoptotic proteins and to be more prone to activate caspase 3.
All this data suggest that 15-PGDH is a promising target for chemoprevention. Discovery and development of agents improving 15-PGDH expression and/or activity in HCC cells will provide additional approaches to cancer chemoprevention. Dexamethasone and other glucocorticoids were found to induce the expression of 15-PGDH in lung cancer cells . Non-steroidal anti-inflammatory drugs (NSAIDs) have been also evaluated exhibiting flurbiprofen the best capacity to induce 15-PGDH (Tai, Chi, 2011) . Furthermore, peroxisome proliferator-activated receptor γ ligands such as thiazolidinediones inhibit lung cancer cell growth by decreasing PGE 2 production through induction of 15-PGDH (Hazra et al. , 2007) . Rosiglitazone specifically decreased expression of Snail which is involved in 15-PGDH suppression (Choudhary et al. , 2010) . In this sense and while we were preparing this manuscript, Lu et al. reported that 15-PGDH inhibits HCC growth through an alternative mechanism involving 15-keto-PGE 2 /PPARγ-mediated activation of p21 WAF1/Cip1 signaling cascade (Lu et al. , 2013) . Finally a promising target is the prostaglandin transporter (PTG) which may collaborate with 15-PGDH to inactivate PGE 2 .
In summary, we have found that the prostaglandin catabolic enzyme, 15-PGDH is 
